These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The new indirubin derivative inhibitors of glycogen synthase kinase-3, 6-BIDECO and 6-BIMYEO, prevent tau phosphorylation and apoptosis induced by the inhibition of protein phosphatase-2A by okadaic acid in cultured neurons. Martin L; Magnaudeix A; Wilson CM; Yardin C; Terro F J Neurosci Res; 2011 Nov; 89(11):1802-11. PubMed ID: 21826701 [TBL] [Abstract][Full Text] [Related]
5. Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease. Jiang X; Zhou J; Wang Y; Chen L; Duan Y; Huang J; Liu C; Chen Y; Liu W; Sun H; Feng F; Qu W Eur J Med Chem; 2020 Dec; 207():112751. PubMed ID: 32950908 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer's disease. Shi XL; Wu JD; Liu P; Liu ZP Eur J Med Chem; 2019 Apr; 167():211-225. PubMed ID: 30772605 [TBL] [Abstract][Full Text] [Related]
7. Inactivation of GSK-3beta in okadaic acid-induced neurodegeneration: relevance to Alzheimer's disease. Yoon SY; Choi JE; Huh JW; Hwang O; Nam Hong H; Kim D Neuroreport; 2005 Feb; 16(3):223-7. PubMed ID: 15706224 [TBL] [Abstract][Full Text] [Related]
8. Flow cytometry-based method to analyze the change in Tau phosphorylation in a hGSK-3beta and hTau over-expressing EcR-293 cell line. Kurko D; Boros A; Dezso P; Urbányi Z; Sárvári M; Nagy J; Szombathelyi Z; Szendrei GI Neurochem Int; 2006 Apr; 48(5):374-82. PubMed ID: 16420965 [TBL] [Abstract][Full Text] [Related]
9. Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors. Prati F; De Simone A; Bisignano P; Armirotti A; Summa M; Pizzirani D; Scarpelli R; Perez DI; Andrisano V; Perez-Castillo A; Monti B; Massenzio F; Polito L; Racchi M; Favia AD; Bottegoni G; Martinez A; Bolognesi ML; Cavalli A Angew Chem Int Ed Engl; 2015 Jan; 54(5):1578-82. PubMed ID: 25504761 [TBL] [Abstract][Full Text] [Related]
10. Development of a cellular tau enzyme-linked immunosorbent assay method for screening GSK-3β inhibitors. Cho GW; Noh MY; Kang BY; Ku IW; Park J; Hong YH; Kim MH; Kim SH Assay Drug Dev Technol; 2011 Oct; 9(5):503-13. PubMed ID: 21561378 [TBL] [Abstract][Full Text] [Related]
11. Discovery of novel harmine derivatives as GSK-3β/DYRK1A dual inhibitors for Alzheimer's disease treatment. Qiu J; Feng X; Chen H; Liu W; Liu W; Wu L; Gao X; Liu Y; Huang Y; Gong H; Qi Y; Xu Z; Zhao Q Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300404. PubMed ID: 38010470 [TBL] [Abstract][Full Text] [Related]
12. Truncation and activation of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease. Jin N; Yin X; Yu D; Cao M; Gong CX; Iqbal K; Ding F; Gu X; Liu F Sci Rep; 2015 Feb; 5():8187. PubMed ID: 25641096 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A. Martin L; Magnaudeix A; Esclaire F; Yardin C; Terro F Brain Res; 2009 Feb; 1252():66-75. PubMed ID: 19071093 [TBL] [Abstract][Full Text] [Related]
14. Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study. Llorach-Pares L; Nonell-Canals A; Avila C; Sanchez-Martinez M Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30332805 [TBL] [Abstract][Full Text] [Related]
15. Stimulation of EphB2 attenuates tau phosphorylation through PI3K/Akt-mediated inactivation of glycogen synthase kinase-3β. Jiang J; Wang ZH; Qu M; Gao D; Liu XP; Zhu LQ; Wang JZ Sci Rep; 2015 Jun; 5():11765. PubMed ID: 26119563 [TBL] [Abstract][Full Text] [Related]
16. Maintained activity of glycogen synthase kinase-3beta despite of its phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model. Lim YW; Yoon SY; Choi JE; Kim SM; Lee HS; Choe H; Lee SC; Kim DH Biochem Biophys Res Commun; 2010 Apr; 395(2):207-12. PubMed ID: 20362550 [TBL] [Abstract][Full Text] [Related]
17. Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines. Berg S; Bergh M; Hellberg S; Högdin K; Lo-Alfredsson Y; Söderman P; von Berg S; Weigelt T; Ormö M; Xue Y; Tucker J; Neelissen J; Jerning E; Nilsson Y; Bhat R J Med Chem; 2012 Nov; 55(21):9107-19. PubMed ID: 22489897 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 3-benzisoxazolyl-4-indolylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3β. Ye Q; Li M; Zhou Y; Pang T; Xu L; Cao J; Han L; Li Y; Wang W; Gao J; Li J Molecules; 2013 May; 18(5):5498-516. PubMed ID: 23669633 [TBL] [Abstract][Full Text] [Related]
19. Helicobacter pylori filtrate induces Alzheimer-like tau hyperphosphorylation by activating glycogen synthase kinase-3β. Wang XL; Zeng J; Yang Y; Xiong Y; Zhang ZH; Qiu M; Yan X; Sun XY; Tuo QZ; Liu R; Wang JZ J Alzheimers Dis; 2015; 43(1):153-65. PubMed ID: 25079798 [TBL] [Abstract][Full Text] [Related]
20. Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase-3β Signaling Pathway in an Alzheimer's Disease Model. Long ZM; Zhao L; Jiang R; Wang KJ; Luo SF; Zheng M; Li XF; He GQ CNS Neurosci Ther; 2015 Nov; 21(11):887-97. PubMed ID: 26385876 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]